Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Therapies for sepsis. Emerging therapies for sepsis and septic shock.

Literature DB >> 9143195

Therapies for sepsis. Emerging therapies for sepsis and septic shock.

E Abraham¹.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 1997 PMID： 9143195 PMCID： PMC1304118

Source DB: PubMed Journal: West J Med ISSN： 0093-0415

× No keyword cloud information.

22 in total

1. Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha, and interferon-gamma in the serum of patients with septic shock. Swiss-Dutch J5 Immunoglobulin Study Group.

Authors: T Calandra; J D Baumgartner; G E Grau; M M Wu; P H Lambert; J Schellekens; J Verhoef; M P Glauser
Journal: J Infect Dis Date: 1990-05 Impact factor: 5.226

2. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia.

Authors: K J Tracey; Y Fong; D G Hesse; K R Manogue; A T Lee; G C Kuo; S F Lowry; A Cerami
Journal: Nature Date: 1987 Dec 17-23 Impact factor: 49.962

3. Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF alpha).

Authors: L B Hinshaw; P Tekamp-Olson; A C Chang; P A Lee; F B Taylor; C K Murray; G T Peer; T E Emerson; R B Passey; G C Kuo
Journal: Circ Shock Date: 1990-03

4. The cardiovascular response of normal humans to the administration of endotoxin.

Authors: A F Suffredini; R E Fromm; M M Parker; M Brenner; J A Kovacs; R A Wesley; J E Parrillo
Journal: N Engl J Med Date: 1989-08-03 Impact factor: 91.245

5. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever.

Authors: J G Cannon; R G Tompkins; J A Gelfand; H R Michie; G G Stanford; J W van der Meer; S Endres; G Lonnemann; J Corsetti; B Chernow
Journal: J Infect Dis Date: 1990-01 Impact factor: 5.226

6. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.

Authors: E J Ziegler; C J Fisher; C L Sprung; R C Straube; J C Sadoff; G E Foulke; C H Wortel; M P Fink; R P Dellinger; N N Teng
Journal: N Engl J Med Date: 1991-02-14 Impact factor: 91.245

7. Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition.

Authors: S Okusawa; J A Gelfand; T Ikejima; R J Connolly; C A Dinarello
Journal: J Clin Invest Date: 1988-04 Impact factor: 14.808

8. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group.

Authors: J Cohen; J Carlet
Journal: Crit Care Med Date: 1996-09 Impact factor: 7.598

9. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli.

Authors: E J Ziegler; J A McCutchan; J Fierer; M P Glauser; J C Sadoff; H Douglas; A I Braude
Journal: N Engl J Med Date: 1982-11-11 Impact factor: 91.245

10. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia.

Authors: Y Fong; K J Tracey; L L Moldawer; D G Hesse; K B Manogue; J S Kenney; A T Lee; G C Kuo; A C Allison; S F Lowry
Journal: J Exp Med Date: 1989-11-01 Impact factor: 14.307

3 in total